2014 - Fellow of the American Statistical Association (ASA)
The scientist’s investigation covers issues in Immunology, Virology, Antibody, Virus and Vaccination. His Immunology study integrates concerns from other disciplines, such as HIV vaccine and AIDSVAX. His work carried out in the field of Virology brings together such families of science as Epitope, Antigen and AIDS Vaccines.
Peter B. Gilbert combines subjects such as Glycoprotein and Immunity with his study of Antibody. Peter B. Gilbert interconnects Internal medicine, Randomized controlled trial and Plasmodium falciparum in the investigation of issues within Vaccination. His work deals with themes such as Placebo, Serostatus, Acquired immunodeficiency syndrome and Viral load, which intersect with Internal medicine.
His primary areas of investigation include Immunology, Virology, Vaccine efficacy, HIV vaccine and Vaccination. His Immunology study frequently links to adjacent areas such as Clinical trial. His research in Virology intersects with topics in Epitope and Antigen.
The Vaccine efficacy study combines topics in areas such as Dengue vaccine, Dengue fever, Intensive care medicine, Disease and HVTN 505. Peter B. Gilbert has included themes like AIDS Vaccines and Statistics, Proportional hazards model in his HIV vaccine study. Peter B. Gilbert has researched Vaccination in several fields, including Placebo, Immunity, Immunogenicity and AIDSVAX.
His primary areas of study are Vaccine efficacy, Vaccination, Antibody, Immunology and Internal medicine. His study in Vaccine efficacy is interdisciplinary in nature, drawing from both Placebo and Disease. His Placebo research integrates issues from Clinical trial and Monoclonal antibody.
His research integrates issues of Antibody response, Immune system, HIV vaccine and Immunogen in his study of Vaccination. His research investigates the connection between Antibody and topics such as Virology that intersect with problems in Epitope. His HVTN 505 research extends to the thematically linked field of Immunology.
Peter B. Gilbert mostly deals with Immunology, Vaccine efficacy, Vaccination, Antibody and Viral load. His Immunology study combines topics from a wide range of disciplines, such as HVTN 505, HIV vaccine, Transcriptome and Upstream and downstream. Peter B. Gilbert works mostly in the field of Vaccine efficacy, limiting it down to concerns involving Placebo and, occasionally, Internal medicine, Randomized controlled trial and Disease.
His studies in Vaccination integrate themes in fields like Adverse effect, Gene and Mediator. His Antibody research incorporates elements of Virus and Virology. His Viral load research includes elements of Clinical trial and Mean squared error, Statistics, Statistical model, Estimator.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
Lindsey R. Baden;Hana M El Sahly;Brandon J Essink;Karen Kotloff.
The New England Journal of Medicine (2021)
Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial
Barton F. Haynes;Peter B. Gilbert;M. Juliana McElrath;Susan Zolla-Pazner.
The New England Journal of Medicine (2012)
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.
Susan P Buchbinder;Devan V Mehrotra;Ann Duerr;Daniel W Fitzgerald.
The Lancet (2008)
Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies
Ming Li;Feng Gao;John R. Mascola;Leonidas Stamatatos.
Journal of Virology (2005)
Randomized, Double‐Blind, Placebo‐Controlled Efficacy Trial of a Bivalent Recombinant Glycoprotein 120 HIV‐1 Vaccine among Injection Drug Users in Bangkok, Thailand
Punnee Pitisuttithum;Peter Gilbert;Marc Gurwith;William Heyward.
The Journal of Infectious Diseases (2006)
Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies.
Michael S. Seaman;Holly Janes;Natalie Hawkins;Lauren E. Grandpre.
Journal of Virology (2010)
Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine
Scott M. Hammer;Magdalena E. Sobieszczyk;Holly Janes;Shelly T. Karuna.
The New England Journal of Medicine (2013)
Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana.
Sheri Weiser;William Wolfe;William Wolfe;David Bangsberg;Ibou Thior.
Journal of Acquired Immune Deficiency Syndromes (2003)
Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study.
Ibou Thior;Shahin Lockman;Laura M Smeaton;Roger L Shapiro.
Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy
Saranya Sridhar;Alexander Luedtke;Edith Langevin;Ming Zhu.
The New England Journal of Medicine (2018)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: